Alumis Inc.
ALMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001847367
In the last 90 days, Alumis Inc. insiders filed 1 open-market purchase and 8 sales; 198 institutions reported holding it in 13F filings for Q2 2026, worth $3.32B in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $10.7M in total
- 1
- Insider sellsLast 90 days, $1.55M in total
- 8
- 13F holdersQ2 2026, +5 vs. previous quarter
- 198
- 13F valueReported value at the end of Q2 2026
- $3.32B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ALMS, Q2 2026
No superinvestor reported holding ALMS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Alumis Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)9:39 PM ET | Sep 4-8 | 5 days | Akkaraju SrinivasDirector | PPurchase | +986.7K | $10.87 | +$10.7M | +75.2%2.30M after | 4 lots |
| Sep 9, 2026 (view filing)9:39 PM ET | Sep 8 | 1 day | Akkaraju SrinivasDirector | SSale | −96.1K | $10.55 | −$1.01M | −4.5%2.03M after | 2 lots |
| Aug 5, 2026 (view filing)6:50 PM ET | Aug 3 | 2 days | Schroer John R.Chief Financial Officer | SSale | −3.28K | $26.37 | −$86.5K | −11.7%24.7K after | |
| Aug 5, 2026 (view filing)6:46 PM ET | Aug 3 | 2 days | Pangali SanamChief Legal Officer | SSale | −1.36K | $26.37 | −$36.0K | −12.3%9.75K after | |
| Aug 5, 2026 (view filing)6:44 PM ET | Aug 3 | 2 days | Hardiman Roy C.Chief Business & Strategy Ofcr | SSale | −2.69K | $26.37 | −$71.0K | −1.3%207.7K after | |
| Aug 5, 2026 (view filing)6:40 PM ET | Aug 3 | 2 days | Goldstein David MChief Scientific Officer | SSale | −2.60K | $26.37 | −$68.5K | −7.7%31.0K after | |
| Aug 5, 2026 (view filing)6:36 PM ET | Aug 3 | 2 days | Drappa JornChief Medical Officer | SSale | −2.45K | $26.37 | −$64.5K | −4.1%56.9K after | |
| Aug 5, 2026 (view filing)6:21 PM ET | Aug 3 | 2 days | Bradley Mark ChristopherChief Development Officer | SSale | −2.57K | $26.37 | −$67.8K | −5.0%48.5K after | |
| Jul 8, 2026 (view filing)4:40 PM ET | Jul 6 | 2 days | Pangali SanamChief Legal Officer | SSale | −5.00K | $28.00 | −$140.0K | −31.0%11.1K after | |
| Jan 13, 2026 (view filing) | Jan 9 | 4 days | Akkaraju SrinivasDirector | PPurchase | +588.2K | $17.00 | +$10.0M | +46.5%1.85M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Alumis Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | 15,139,707 | $426.0M | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,218,151 | $231.3M | 0.00% | +1,047,283+14.6% | Added |
| FMR LLC | 6,769,170 | $190.5M | 0.01% | +5,795,388+595.1% | Added |
| Deep Track Capital, LP | 6,348,558 | $178.6M | 2.63% | −424,037−6.3% | Reduced |
| Samsara BioCapital, LLC | 6,345,219 | $178.6M | 14.67% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 5,896,995 | $165.9M | 45.81% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 5,199,838 | $146.3M | 0.01% | +1,913,085+58.2% | Added |
| venBio Partners LLC | 4,528,408 | $127.4M | 24.53% | 00.0% | Unchanged |
| Foresite Capital Management VI LLC | 4,247,670 | $119.5M | 18.60% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,215,703 | $118.6M | 0.00% | +183,437+4.5% | Added |